Guardian Pharmacy Services, Inc. is a US-listed company in the health care services industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Guardian Pharmacy Services, Inc. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Revenue for the twelve months to June 2026 was $1.46bn. Free-cash-flow margin rose to 5.2% from 2.8% a year earlier. Operating margin widened to 5.8% from -4.7%. It passes 3 of our 3 financial-health checks.
Our model value for Guardian Pharmacy Services is under review, so past values are not shown until it is resolved.
Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Guardian Pharmacy Services, Inc.'s trailing-twelve-month revenue grew 10.3% year on year, with a free-cash-flow margin of 5.2%.
Current signal Net margin expanding: TTM net margin reached 4.5%, up 11.4pp year over year.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
The company also guided to adjusted ebitda of $129.00m to $131.00m for the FY 2026 Outlook.
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Guardian Pharmacy Services, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.2%: the 10-year Treasury yield (4.9%) plus a beta of 0.71 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$19 ~$13–$22 | Primary model, counts double |
| Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. | ~$25 ~$21–$37 | Included |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Guardian Pharmacy Services, Inc. with Health Care Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Next results: November 5, 2026, after the close. Analysts expect revenue of $366m and EPS of $0.31 (range $0.29 to $0.33) for the quarter.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | $1.30 | +22% | $1.4bn | −1% |
| Next | $1.43 | +10% | $1.5bn | +6% |
Next year's EPS estimate has moved +5.6% in 90 days, across 7 analysts.
The consensus EPS forecast for the current fiscal year is +3.3% on 90 days ago. In the last 30 days, 4 analysts raised Guardian Pharmacy Services, Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | $1.26 | $1.36 |
| 60 days ago | $1.30 | $1.43 |
| 30 days ago | $1.30 | $1.43 |
| 7 days ago | $1.30 | $1.43 |
| Now | $1.30 | $1.43 |
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | $0.26 | $0.29 | +10.8% |
| Mar 2026 | $0.24 | $0.29 | +20.8% |
| Dec 2025 | $0.27 | $0.37 | +38.3% |
| Sept 2025 | $0.23 | $0.25 | +6.4% |
Adjusted EPS as companies report it, against the average analyst estimate.
| Calendar year | 2025 | 2026 to date |
|---|---|---|
| Return | ||
| GRDN | +49% | +33% |
| Industry peers (median) | −9% | +15% |
| S&P 500 | +18% | +11% |
| Months that ended higher | ||
| GRDN | 67% | 55% |
| S&P 500 | 75% | 46% |
| Largest fall from a high during the year | ||
| GRDN | −26% | −19% |
| S&P 500 | −19% | −9% |
Worst fall since September 26, 2024: 27% from December 12, 2024 to March 6, 2025. Getting back needed a 37% gain, reached on May 2, 2025, 57 days after the low.
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 6, 2026 | +8.2% | +0.5% | −5.0% | +0.7% |
| May 6, 2026 | −2.6% | +1.1% | −4.2% | +8.7% |
| March 11, 2026 | −1.1% | −1.6% | +0.8% | +16.3% |
| January 13, 2026 | −4.4% | −0.7% | −6.9% | +5.2% |
| November 10, 2025 | +8.5% | +1.8% | −1.6% | +3.9% |
| August 11, 2025 | +13.3% | +0.9% | +24.3% | +45.1% |
| May 12, 2025 | −3.9% | +4.0% | +3.5% | −21.3% |
| March 26, 2025 | +3.8% | −1.5% | +5.9% | +19.0% |
| March 3, 2025 | −2.0% | −2.9% | −8.1% | +5.0% |
| November 12, 2024 | −11.0% | −0.3% | −3.1% | +13.1% |
Source: SEC EDGAR filings. Retrieved October 26, 2026.
| Period | Revenue (TTM) |
|---|---|
| FY24 Q4 | $1.2B |
| FY25 Q1 | $1.3B |
| FY25 Q2 | $1.3B |
| FY25 Q3 | $1.4B |
| FY25 Q4 | $1.4B |
| FY26 Q1 | $1.5B |
| FY26 Q2 | $1.5B |
Source: SEC EDGAR filings. Retrieved October 26, 2026.
| Period | Operating margin (TTM) |
|---|---|
| FY24 Q4 | -5.1% |
| FY25 Q1 | -4.5% |
| FY25 Q2 | -4.7% |
| FY25 Q3 | 4.2% |
| FY25 Q4 | 5.0% |
| FY26 Q1 | 5.3% |
| FY26 Q2 | 5.8% |
Source: SEC EDGAR filings. Retrieved October 26, 2026.
| Period | FCF margin (TTM) |
|---|---|
| FY24 Q4 | 3.1% |
| FY25 Q1 | 3.6% |
| FY25 Q2 | 2.8% |
| FY25 Q3 | 4.8% |
| FY25 Q4 | 5.4% |
| FY26 Q1 | 4.5% |
| FY26 Q2 | 5.2% |
Each dollar Guardian Pharmacy Services took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.
| Revenue | $1.4B | |
|---|---|---|
| Cost of revenue | $1.2B | 79.8% of revenue |
| Gross profit | $293M | 20.2% of revenue |
| Selling, general and admin | $220M | 15.2% of revenue |
| Operating income | $72.7M | 5.0% of revenue |
| Income tax | $24.5M | 1.7% of revenue |
| Net income | $49.2M | 3.4% of revenue |
| Fiscal year | 2024 Dec 2024 | 2025 Dec 2025 | LTM Jun 2026 |
|---|---|---|---|
| Income | |||
| Revenue | 1,228 | 1,449 | 1,463 |
| Gross profit | 244 | 293 | 317 |
| EBITDA | −43 | 95 | 109 |
| Operating income | −63 | 73 | 85 |
| Net income | −110 | 49 | 66 |
| Growth (year on year) | |||
| Revenue | — | +17.9% | +10.3% |
| Margins | |||
| Gross margin | 19.9% | 20.2% | 21.6% |
| EBITDA margin | −3.5% | 6.6% | 7.4% |
| Operating margin | −5.1% | 5.0% | 5.8% |
| Net margin | −9.0% | 3.4% | 4.5% |
| Free-cash-flow margin | 3.5% | 6.0% | — |
| Cash flow | |||
| Cash from operations | 58 | 100 | 99 |
| Capital spending | 15 | 13 | — |
| Free cash flow | 43 | 87 | — |
| Stock-based pay | 131 | 14 | 10 |
| Free cash flow after stock pay | −88 | 73 | — |
| Balance sheet | |||
| Cash | 5 | 66 | 90 |
| Total debt | 0 | 0 | 0 |
| Net debt (negative = net cash) | −5 | −66 | −90 |
| Quarter | 2024 Q3 Sept 2024 | 2024 Q4 Dec 2024 | 2025 Q1 Mar 2025 | 2025 Q2 Jun 2025 | 2025 Q3 Sept 2025 | 2025 Q4 Dec 2025 | 2026 Q1 Mar 2026 | 2026 Q2 Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 314 | 339 | 329 | 344 | 377 | 398 | 337 | 352 |
| Gross profit | 61 | 67 | 64 | 68 | 75 | 86 | 76 | 80 |
| EBITDA | −100 | 22 | 18 | 18 | 22 | 37 | 24 | 26 |
| Operating income | −105 | 17 | 13 | 13 | 16 | 31 | 18 | 21 |
| Net income | −122 | 12 | 9 | 9 | 10 | 21 | 13 | 22 |
| Growth (year on year) | ||||||||
| Revenue | +19.7% | — | +19.6% | +14.8% | +20.0% | +17.4% | +2.2% | +2.2% |
| EBITDA | — | — | +44.1% | −17.4% | — | +66.6% | +29.4% | +46.4% |
| Operating income | — | — | +63.9% | −26.0% | — | +83.6% | +35.9% | +64.1% |
| Net income | — | — | +33.2% | — | — | +75.2% | +40.7% | +142.2% |
| Margins | ||||||||
| Gross margin | 19.4% | 19.8% | 19.5% | 19.8% | 19.8% | 21.5% | 22.7% | 22.8% |
| EBITDA margin | −31.7% | 6.5% | 5.5% | 5.2% | 5.9% | 9.2% | 7.0% | 7.5% |
| Operating margin | −33.3% | 4.9% | 3.9% | 3.7% | 4.3% | 7.7% | 5.3% | 5.9% |
| Net margin | −38.8% | 3.5% | 2.9% | 2.6% | 2.6% | 5.3% | 3.9% | 6.2% |
| Free-cash-flow margin | −1.4% | 5.9% | — | — | 6.4% | 8.6% | — | 8.5% |
| Cash flow | ||||||||
| Cash from operations | −2 | 22 | 18 | 20 | 28 | 35 | 6 | 30 |
| Capital spending | 2 | 2 | — | — | 4 | 0 | — | 0 |
| Free cash flow | −4 | 20 | — | — | 24 | 34 | — | 30 |
| Stock-based pay | 122 | 3 | 4 | 4 | 4 | 1 | 2 | 3 |
| Free cash flow after stock pay | −127 | 17 | — | — | 20 | 33 | — | 27 |
| Last 12 months unless stated | GRDN | ADUS | PIII | HQY | PGNY | GH | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $1.5bn | $1.5bn | $1.5bn | $1.4bn | $1.3bn | $1.2bn | $1.2bn |
| Revenue growth, last 12 months | 10.3% | 15.9% | 2.8% | 7.3% | 5.5% | 42.7% | 7.4% |
| Revenue growth, 3-year average | — | 13.9% | 9.7% | 13.2% | 11.0% | 32.4% | 11.3% |
| Revenue growth, latest quarter | 2.2% | 8.0% | 8.6% | 7.6% | 5.3% | 44.3% | 8.5% |
| Gross margin | 21.6% | 32.4% | — | 71.2% | 24.6% | 65.0% | 27.8% |
| Operating margin | 5.8% | 10.0% | −9.9% | 25.8% | 8.6% | −39.7% | 2.6% |
| Operating margin, 3-year average | — | 9.4% | −14.7% | 19.9% | 7.0% | −58.3% | 2.3% |
| Net margin | 4.5% | 7.1% | −6.6% | 17.4% | 6.0% | −38.3% | 1.2% |
| Cash from operations / revenue | 6.8% | 11.0% | −8.7% | 36.0% | 15.4% | −15.7% | 6.3% |
| Free-cash-flow margin | 5.2% | 10.5% | −8.7% | 35.8% | 13.6% | −20.3% | 5.1% |
| Free-cash-flow margin, 3-year average | — | 8.9% | −7.1% | 30.8% | 14.7% | −33.2% | 3.6% |
| Stock pay / revenue | 0.7% | 1.2% | 0.3% | 6.0% | 8.2% | 16.2% | 1.0% |
| Change in share count | — | 0.8% | 40.0% | −3.3% | −4.2% | 4.6% | 0.3% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| FMR LLC | $136M | 3.2M | 11.1% | ▲ 37.4% |
| Wellington Management Group LLP | $72.4M | 1.7M | 5.9% | ▼ 2.0% |
| Blackrock, Inc. | $66M | 1.6M | 5.4% | ▼ 10.3% |
| Vanguard Capital Management LLC | $57.8M | 1.4M | 4.7% | ▲ 12.6% |
| Woodline Partners LP | $54.7M | 1.3M | 4.5% | 0.0% |
| Valiant Capital Management, L.P. | $49.7M | 1.2M | 4.1% | 0.0% |
| T. Rowe Price Investment Management, Inc. | $46.8M | 1.1M | 3.8% | ▲ 8.6% |
| Boston Partners | $40.8M | 984K | 3.3% | ▼ 3.3% |
| Franklin Resources Inc | $40.5M | 966K | 3.3% | ▲ 1.4% |
| Timessquare Capital Management, LLC | $39.8M | 952K | 3.2% | ▼ 11.7% |
| Loomis Sayles & Co L P | $36.4M | 870K | 3.0% | ▼ 6.6% |
| Boone Capital Management LLC | $29.8M | 712K | 2.4% | ▲ 12.8% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Guardian Pharmacy Services, Inc.'s complete shareholder register. Values are as reported by the filers .
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Cardinal Equity Fund, L.P. 10% owner | March 20, 2026 | Sell | 275,728 | $29.68 | $8.2M |
| Forbes Kendall See Remarks | March 20, 2026 | Sell | 346,672 | $29.68 | $10.3M |
| Bindley William E Director | March 20, 2026 | Sell | 3,570,677 | $29.68 | $106M |
| Ackerman John Director | March 20, 2026 | Sell | 827,636 | $29.68 | $24.6M |
| Ackerman John Director | March 20, 2026 | Sell | 275,728 | $29.68 | $8.2M |
| Bindley Capital Partners I, Llc 10% owner | March 20, 2026 | Sell | 3,570,677 | $29.68 | $106M |
| Salentine Thomas J Jr Director | March 20, 2026 | Sell | 3,570,677 | $29.68 | $106M |
| Morris David K See Remarks | March 20, 2026 | Sell | 187,855 | $29.68 | $5.6M |
| Burke Fred See Remarks | March 20, 2026 | Sell | 671,432 | $29.68 | $19.9M |
| Pharmacy Investors, Llc 10% owner | March 20, 2026 | Sell | 827,636 | $29.68 | $24.6M |
| Cosler Steven D Director | December 3, 2025 | Buy | 3,370 | $29.61 | $99,786 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| Financial statements | SEC 10-K and 10-Q filings | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
